Table of contents
- Overview of the clinical trials
- Settings and patient populations
- Study design and main endpoints
- Trial-by-trial summary
- What patients should know about these studies
Overview of the clinical trials
These studies investigate Ropivacaine in different clinical settings where pain control is important.[1][2][3][4][5]
Most of the trials are Phase 3 studies, which usually compare treatments in larger groups of patients.[1][2][3][5] One study is listed as Low Intervention, meaning it uses a low-risk research approach rather than a standard drug development phase label.[4]
The studies are interventional, which means researchers assign a treatment or procedure and then measure the results.[1][2][3][4][5]
Settings and patient populations
The trials include people in intensive care during pleural drainage, patients having throat and neck cancer surgery, patients having cardiac sternotomy surgery, people with hemorrhoidal disease undergoing radiofrequency treatment, and patients having hallux valgus repair surgery.[1][2][3][4][5]
These are not general studies for all patients; each trial focuses on a specific procedure or condition.[1][2][3][4][5]
In the cancer surgery study, the goal is to reduce the amount of IV morphine used in the first 24 hours after surgery.[2] In the hallux valgus study, the focus is on ankle blocks and how long the sensory block lasts.[5]
Study design and main endpoints
The main endpoint is the main result the researchers want to measure.[1][2][3][4][5]
In the pleural drainage study, the main endpoint is the intensity of acute pain during drainage, measured with a numerical scale.[1]
In the throat and neck cancer surgery study, the main endpoint is the amount of morphine used after the operation, including morphine given in the recovery room and through PCA.[2]
In the cardiac sternotomy study, the main endpoint is the change in forced vital capacity (FVC), which is a measure of how much air a person can blow out after surgery.[3]
In the hemorrhoid procedure study, the main endpoint is the pain score on the visual analogue scale (VAS) six hours after the procedure starts.[4]
In the hallux valgus study, the main endpoint is the difference in the duration of the sensory blocks over a 48-hour period.[5]
Trial-by-trial summary
NCT03984656 studies a serratus plane block during pleural drainage in intensive care, comparing it with local anesthesia to see how well it controls acute pain.[1] The trial is Phase 3, is authorised, and plans to include 70 participants.[1]
2024-510942-15-00 studies a superficial cervical plexus block in oncological throat and neck surgery, with the goal of lowering postoperative morphine use in the first 24 hours.[2] This trial is Phase 3, authorised, and has an enrollment of 346 participants.[2]
2024-513301-30-00 studies a parasternal analgesic block after cardiac sternotomy surgery to assess postoperative breathing function.[3] It is a Phase 3 study, completed, with 84 participants.[3]
NCT05519189 studies perianal infiltration during radiofrequency treatment of hemorrhoidal disease and compares pain at six hours after the procedure.[4] It is completed, has a Low Intervention design, and includes 134 participants.[4]
NCT06185608 studies different concentrations of Ropivacaine for ultrasound-guided ankle blocks in hallux valgus repair surgery, with a focus on how long the sensory block lasts.[5] It is a Phase 3 study, authorised, and plans to enroll 174 participants.[5]
What patients should know about these studies
These trials are designed to answer practical questions about pain relief, recovery, and the effect of locoregional anesthesia in specific procedures.[1][2][3][4][5]
Some studies compare Ropivacaine with another approach, while others look at different concentrations or techniques used with Ropivacaine.[1][4][5]
The results are measured with patient-relevant outcomes such as pain scores, opioid use, and breathing function after surgery.[1][2][3][4][5]





